In this week’s issue:
- The CIHR Foundation Scheme Stage 2 deadline to receive application packages for Faculty approval is Wednesday, January 28th. Full application procedures & timelines are available at https://mednet.med.ubc.ca/Research/GrantApplications/CIHR/Pages/CIHR-Foundation-Scheme-2014-1st-Live-Pilot.aspx.
- Simons Foundation – Novel Outcome Measures for ASD Clinical Trials (reminder)
- Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials
- National Ataxia Foundation – 2015 Research Program
- Benign Essential Blepharospasm Research Foundation – Requests for Proposals
Awards and Honours:
- Confederation of University Faculty Associations of British Columbia – Distinguished Academics Awards
- UBC Faculty of Medicine Continuing Professional Development – Medical Disorders and Pregnancy
- UBC Faculty of Medicine Continuing Professional Development – 12th Annual Pediatric Emergency Medicine Update & Advanced Pediatric Life Support (APLS)
- UBC Medical Journal Call for New Submissions
Notice of Intent Deadline: February 5, 2015
Application Deadline: February 23, 2015; 2pm
The mission of the Simons Foundation Autism Research Initiative is to improve the diagnosis and treatment of autism spectrum disorders.
Through its 2015 Novel Outcome Measures for ASD Clinical Trials, the foundation will award grants of up to $500,000 over two years for research that aims to develop and validate objective outcome measures for use in clinical trials targeting core symptoms (social communication impairments and restricted, repetitive behaviors) of autism spectrum disorder, as well as disruptive behavioral symptoms commonly reported in individuals with autism (e.g., anxiety, tantrums).
Priority will be given to projects that measure behaviors, skills, or biomarkers that have relevance to one or more core autism domains of socialization, language, and repetitive behavior, and that co-vary with autism severity; are objective and yield continuous quantitative data of sufficient range; are feasible in terms of burden on participants and families; capture data (when possible) from participants in their natural environment rather than exclusively in the laboratory setting; and are scalable and affordable for large clinical trials (e.g., between three hundred and a thousand participants).
Examples of possible approaches include but are not limited to clinician-rated measures, language sampling tasks, combined measures of physiological data and observational behavioral data, eye-tracking, and electroencephalography paradigms.
All applicants and key collaborators must hold a Ph.D., M.D., or equivalent degree and have a faculty position or the equivalent at a college, university, medical school, or other research facility. Applications may be submitted by domestic and foreign nonprofit organizations; public and private institutions, such as colleges, universities, hospitals, laboratories, and units of state and local government; and eligible agencies of the federal government. There are no citizenship or national residence requirements.
See the Simons Foundation website for complete program guidelines and application instructions.
LOI Deadline: Two weeks before application deadlines – see below
The Alzheimer’s Drug Discovery Foundation is accepting proposals for clinical trials of innovative drugs to treat Alzheimer’s disease.
Through its Program to Accelerate Clinical Trials, the foundation will award grants of up to $1.5 million for biomarker-based pilot clinical trials of Alzheimer drugs at the proof-of-concept phase. The foundation is particularly interested in projects aimed at testing drugs approved for other indications in Alzheimer’s disease, as well as therapies that address energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, and the blood-brain barrier interface.
Nonprofit academic institutions and for-profit biotechnology companies are eligible to apply.
Deadlines in 2015 for full proposals are March 10, June 16, September 22, and December 10. Letters of Intent are required at least two weeks prior to the application deadline.
See the ADDF website for complete program guidelines and application instructions.
Deadlines: See below
The National Ataxia Foundation is committed to funding the best science relevant to hereditary and sporadic types of ataxia in both basic and translational research. To that end, the foundation is inviting Letters of Intent from international and U.S.-based nonprofit and for-profit institutions for its 2015 research program.
Research Grants: NAF will award seed grants of up to $15,000 for ataxia-related research projects. Grants of up to $30,000 will be considered for early or pilot phases of studies and ongoing investigations. LOIs must be received no later than July 15, 2015. Upon review, selected applicants will be invited to submit full applications, which must be returned by August 17, 2015.
NAF Young Investigator Awards: The foundation offers two funding tracks through its Young Investigator Awards program. The Young Investigator Award provides grants of $35,000 to encourage young investigators to pursue a career in the field of any form of ataxia research. The Young Investigator Award for SCA Research provides one-year grants of $50,000 to encourage young investigators to pursue a career in spinocerebellar ataxia research.
For both Young Investigator award programs, candidates must have attained an M.D. or Ph.D. degree and have an appointment as a junior faculty member, senior post-doc, or clinical fellow. Individuals at the associate professor level are not eligible to apply. In addition, clinicians must have finished their residency no more than five years prior to applying, while Ph.D.s must be no more than five years from completion of their post-doc training. LOIs must be received no later than August 3, 2015. Upon review, selected applicants will be invited to submit full applications by September 1, 2015.
NAF Research Post-Doc Fellowship Award: This program provides one-year grants up to $35,000. Applicants should have completed at least one year of postdoctoral training but not more than two at the time of application, and should be able to demonstrate a commitment to research in the field of ataxia. LOIs must be received no later than August 17, 2015. Upon review, selected applicants will be invited to submit full applications, which are due by September 15, 2015.
NAF Pioneer SCA Research Award Awards: The Pioneer SCA Translational Research Award provides a one-year grant of $100,000 for research designed to facilitate the development of treatments for spinocerebellar ataxias. LOIs must be received no later than August 17, 2015. Upon review, selected applicants will be invited to submit full applications, which must be returned no later than September 15, 2015.
Visit the NAF website for complete program guidelines and application procedures.
Deadline: August 31, 2015
The purpose of the Benign Essential Blepharospasm Research Foundation is to undertake, promote, develop, and carry on the search for the cause of and a cure for benign essential blepharospasm and other related disorders and infirmities of the facial musculature.
To advance this goal, the foundation is inviting applications for research projects directly related to blepharospasm or Meige’s Syndrome, both forms of cranial dystonia. Projects should focus on new treatments, pathophysiology and genetics, photophobia, and dry eye. Grants of up to $150,000 will be awarded.
To be eligible, principal investigators must possess an M.D. or Ph.D. degree. Non-U.S. citizens working at institutions abroad are also eligible to apply.
See the BEBRF website for complete program guidelines and application instructions.
AWARDS AND HONOURS:
Nomination Deadline: January 30, 2015
Do you know a colleague whose research or other scholarly work has had a positive impact on the community beyond the academy? Have they developed or applied an idea that has a significant social, cultural or economic effect? Do they share their research with the community or use it to motivate change?
Each year, the Distinguished Academics Awards recognize the impact scholarly research has outside our universities. Members of the faculty associations at UBC, SFU, UViC, UNBC and RRU are eligible to be nominated for three awards:
Early In Career Award
This award recognizes outstanding contributions made by scholars at relatively early stages in their careers. As a guide only, early in career is often defined as being “no more than five years from completion of a doctoral degree or equivalent” or “within three years of the initial appointment as an Assistant Professor”.
Ehor Boyanowsky Academic of the Year Award
Named in honour of the founder of the Distinguished Academics Awards, this award recognizes specific and recent outstanding contributions to the community beyond the academy through research or other scholarly activity by scholars at any stage of their career.
Paz Buttedahl Career Achievement Award
Named in memory of Dr. Paz Buttedahl – academic, community builder and faculty association leader – this award is for sustained outstanding contributions to the community beyond the academy through research or other scholarly activities by an individual or a group over the major portion of their career.
The deadline for nominations is January 30, 2015
More information and nomination forms available at: www.cufa.bc.ca/awards
Date: April 18, 2015
Location: Sheraton Vancouver Wall Centre, Vancouver
Target audience: Obstetricians, gynecologists, internists, maternal fetal medicine specialists, fellows, residents & students
Up to 7.0 Mainpro-M1/MOC Section 1 credits
Date: May 8-9, 2015 + pre course May 7, 2015
Location: UBC Robson Square, Vancouver
Up to 11.25 Mainpro-M1/MOC Section 1 credits (Regular Conference)
APLS Pre-Course: May 7 (Thu) Up to 7.5 MOC Section 2 / Mainpro-C/M1 credits
Submission Deadline: March 13, 2015
The UBC Medical Journal is currently accepting submissions for our upcoming issue! The theme for this issue is Complementary and Alternative Medicines (CAMs). These historic and diverse medical practices—although given little focus in the MD undergraduate curriculum—have emerged as an important topic in healthcare due to controversies over their use. Debates and ethical quandaries arise when addressing the role of these practices in our society and the limited knowledge of patients and physicians regarding the safety and efficacy of these practices. This controversy gives rise to litigations wherein patients opt for alternative medicines over conventional options. Examples of existing differences between these practices include:
- Funding and coverage under the Canada Health Act
- Necessity for and expectation of evidence-based guidelines
Modern healthcare must come to a consensus on whether to, and how best to address these differences. “Integrated care”, that is to say the incorporation of CAMs into Western medical practice, may improve patient compliance and overall patient welfare but could come at the price of undermining modern evidence-based guidelines. Exploring these issues and developing a new standard of care will help guide physicians in assessing the validity of CAMs and negotiating with patients when alternative practices conflict with the current standard of care.
We look forward to reading submissions addressing any aspect of this topic. Submissions can fall into one of the following categories: Academic Research, Reviews, Commentaries, News and Letters, Global Health, and Case and Elective Reports. We also accept submissions that do not fall into this theme so do not hesitate to submit your work! The submission deadline is Friday, March 13th, 2015 (by 11:59pm). We encourage you to take advantage of this opportunity to publish your work in an internationally recognized academic journal. Publishing in the UBCMJ is an excellent way to make your voice heard on important healthcare topics and to gain experience navigating the submission process for medical journals. We will present the UBCMJ Distinguished Writing Award (and a $250 honorarium) to the strongest article submitted for this issue.